Negative patch test findings after initiation of upadacitinib: A case report

Abstract

Upadacitinib is a systemic Janus kinase inhibitor currently approved for the treatment of atopic dermatitis. Many patients with atopic dermatitis have a concomitant diagnosis of allergic contact dermatitis. The utility of Janus kinase inhibitors for the treatment of allergic contact dermatitis and the effect on patch testing results remains unclear. We present a case of a woman in her 30s with atopic dermatitis and allergic contact dermatitis who was patch test negative after initiating therapy with upadacitinib.